Filter results by document type and/or working area to find what you're searching for.
Being diagnosed with haematologic malignancy actually happens either because the patient presents with certain symptoms or – as is becoming increasingly common – there are incidental findings during routine blood screening. This white paper describes how a complete blood count measured on Sysmex XN-Series analysers may reveal significant abnormalities and improve the incidental findings of haematologic malignancies or the relapse of cancer under treatment early on.
Doping with blood, erythropoietin or related substances is an unfair practice in sports and is performed to obtain an advantage over competing athletes. Doping control has made great progress in detecting the use of forbidden substances by employing completely new strategies that no longer rely on the detection of the banned substance itself. What is measured instead are the changes that forbidden doping practice has on haematological parameters.
Chronic kidney disease (CKD) is a severe complication in context of various civilisation diseases, such as diabetes, hypertension, and obesity. With increasing treatment cost along the progression of CKD towards end-stage renal failure (ESRF) and the need for renal replacement therapies, CKD is not only a driver of premature mortality and diminished quality of life of affected individuals, but also puts significant burden on the society and healthcare expenditures. The early detection of kidney damage through a frequent screening of risk patients could help to fight the burden of CKD. Cost-efficient routine urinalysis data could play a vital role in providing valuable information for screening, diagnosing, and monitoring of renal disorders.
The fluorescence technology and channel-specific reagents of the XN-Series provide much more than just a cell count. Depending on their cell membrane composition, cells are perforated and labelled differently, disclosing information about the cells’ activity, maturity stage, and malignancy. This white paper sheds a light on how the XN measures cell functionality.
Once the analysis results have been technically validated and considered reliable, they can be looked at from a clinical angle to search for suspect results. The task of biomedical validation is to recognise abnormal or conspicuous quantita¬tive results. Based on the findings compiled by the GFHC, there is a new rule set implemented in Extended IPU looking at things such as cut-off values, assessment of previous values or additional patient information. Check out the recommendation from GFHC.
This article describes a comprehensive reference interval study for the Sysmex XE-5000 haematological analyser, covering all diagnostic and many research parameters. A special feature is frequency distribution curves for all examined parameters which provide useful insight on the type of distribution for each test.